MAOB and Alzheimer disease: Interestingly, the design and development of non-selective ChE inhibitors for use in AD appears of valuable pharmacological concern, as the hydrolysis of neurotransmitter ACh may largely occur via BuChE catalysis in aged AD brains, the activity levels of which have been found elevated on late-stages of the disease as it is also the case with MAO B. Since BuChE is also found in glial cells that are recruited and activated around the plaques and tangles, the inhibition of this enzyme might provide additional benefits at reducing neuroinflammation.